Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Ma W, Wei S, Li Q, Zeng J, et al. Mol Cancer Ther 2024;23:700-710.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ma W, Wei S, Li Q, Zeng J, et al. Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models. Mol Cancer Ther 2024;23:700-710.
PMID: 38237027